DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
Conditions:  Malignancy;  Malignant Neoplasm;  Lymphoproliferative Disorders;  Neoplasms by Histologic Type;  Neoplasms by Site;  Cancer;  Colorectal Neoplasms;  Endometrial Neoplasms;  Melanoma Intervention:  Drug: Atezolizumab Sponsors:  Cancer Research UK;  University of Manchester;  University of Birmingham;  Royal Marsden NHS Foundation Trust;  Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer in Young Adults | Gastroschisis Repair | Melanoma | Pediatrics | Research | Skin Cancer